Jazz Pharmaceuticals plc
US ˙ NasdaqGS ˙ IE00B4Q5ZN47

SecurityJAZZ / Jazz Pharmaceuticals plc
InstitutionHolocene Advisors, LP
Latest Disclosed Ownership733,905 shares
Latest Disclosed Value $ 138,744,740
Holocene Advisors, LP ownership in JAZZ / Jazz Pharmaceuticals plc

On May 15, 2026 - Holocene Advisors, LP filed a 13F-HR form disclosing ownership of 733,905 shares of Jazz Pharmaceuticals plc (US:JAZZ) valued at $138,744,740 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 589,735 shares of Jazz Pharmaceuticals plc. This represents a change in shares of 24.45% during the quarter. The current value of the position is $176,181,234 USD.

Holocene Advisors, LP has a history of taking positions in derivatives of the underlying security (JAZZ) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

JAZZ / Jazz Pharmaceuticals plc Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 733,905 144,170 24.45 138,745 38.39 0.3346
2026-02-17 2025-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 589,735 -15,374 -2.54 100,255 25.71 0.2105
2025-11-14 2025-09-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 605,109 135,367 28.82 79,753 59.99 0.1817
2025-08-14 2025-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 469,742 -22,287 -4.53 49,849 -18.39 0.1216
2025-05-15 2025-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 492,029 492,029 61,085 0.1782
2021-08-16 2021-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 0 -4,333 -100.00 0 -100.00
2021-05-17 2021-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 4,333 -667,236 -99.35 712 -99.36 0.0045
2021-02-16 2020-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 671,569 -151,833 -18.44 110,842 -5.59 0.6994
2020-11-16 2020-09-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 823,402 340,749 70.60 117,409 120.46 0.8927
2020-08-14 2020-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 482,653 15,404 3.30 53,256 14.28 0.4668
2020-05-15 2020-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 467,249 298,775 177.34 46,603 85.30 0.5005
2020-02-14 2019-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 168,474 168,474 25,150 0.2254
2018-08-14 2018-06-30 13F JAZZ PHARMACEUTICALS SHS USD G50871105 0 -1,649 -100.00 0 -100.00
2018-05-15 2018-03-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 1,649 -3,072 -65.07 249 -60.85 0.0056
2018-02-14 2017-12-31 13F JAZZ PHARMACEUTICALS SHS USD G50871105 4,721 4,721 636 0.0161
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-05-17 2021-03-31 13F JAZZ PHARMACEUTICALS SHS USD Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-02-16 2020-12-31 13F JAZZ PHARMACEUTICALS SHS USD Call 240,000 4.35 39,612 20.78 n/a n/a n/a
2020-11-16 2020-09-30 13F JAZZ PHARMACEUTICALS SHS USD Call 230,000 32,796 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.